- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| RAPID MICRO BIOSYSTEMS Aktie jetzt für 0€ handeln | |||||
| 07.08. | Rapid Micro Biosystems übertrifft Umsatzprognose für Q2 2026, doch Aktie gibt nach | 4 | Investing.com Deutsch | ||
| 07.08. | RAPID MICRO BIOSYSTEMS, INC. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 07.08. | Rapid Micro Biosystems reports mixed Q2 results; reaffirms FY26 outlook | 3 | Seeking Alpha | ||
| 07.08. | Rapid Micro Biosystems, Inc.: Rapid Micro Biosystems Reports Second Quarter 2026 Financial Results | 672 | GlobeNewswire (Europe) | Reports second quarter 2026 total revenue of $8.1 million, representing 11% growth compared to the second quarter of 2025 Achieved a significant milestone with the 200th Growth Direct system placed... ► Artikel lesen | |
| 07.08. | RAPID MICRO BIOSYSTEMS, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 04.08. | Rapid Micro Biosystems, Inc.: Rapid Micro Biosystems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) | ||
| 23.07. | Rapid Micro Biosystems, Inc.: Rapid Micro Biosystems to Announce Second Quarter 2026 Financial Results on August 7, 2026 | 3 | GlobeNewswire (USA) | ||
| 10.06. | Rapid Micro Biosystems, Inc.: Rapid Micro Biosystems Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) | ||
| 19.05. | Rapid Micro Biosystems prices $9.8M capital raise with up to $21.7M in additional warrant potential | 1 | Seeking Alpha | ||
| 19.05. | Rapid Micro Biosystems, Inc.: Rapid Micro Biosystems Announces Pricing of Up to Approximately $32 Million Underwritten Offering | 2 | GlobeNewswire (USA) | ||
| 15.05. | RAPID MICRO BIOSYSTEMS, INC. - 10-Q, Quarterly Report | 4 | SEC Filings | ||
| 13.05. | Rapid Micro Biosystems GAAP EPS of -$0.31 misses by $0.06, revenue of $8M beats by $0.4M | 2 | Seeking Alpha | ||
| 13.05. | RAPID MICRO BIOSYSTEMS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.05. | Rapid Micro Biosystems, Inc.: Rapid Micro Biosystems Reports First Quarter 2026 Financial Results | 737 | GlobeNewswire (Europe) | Reports first quarter 2026 total revenue of $8.0 million, representing 11% growth compared to the first quarter of 2025 Placed 6 Growth Direct systems in the first quarter 2026 compared to 3 systems... ► Artikel lesen | |
| 06.05. | Rapid Micro Biosystems, Inc.: Rapid Micro Biosystems to Announce First Quarter 2026 Financial Results on May 13, 2026 | 1 | GlobeNewswire (USA) | ||
| 27.03. | RAPID MICRO BIOSYSTEMS, INC. - 8-K, Current Report | 5 | SEC Filings | ||
| 12.03. | Rapid Micro Biosystems, Inc.: Rapid Micro Biosystems Announces Follow-on Multi-System Order from Samsung Biologics to Expand Deployment of Growth Direct Platform | 836 | GlobeNewswire (Europe) | LEXINGTON, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the "Company"), an innovative life sciences technology company providing mission critical automation... ► Artikel lesen | |
| 14.01. | After-Hours Biotech Rally: SXTC, RPID, TGTX Lead Gains On Revenue Updates, And FDA Milestones | 769 | AFX News | BEIJING (dpa-AFX) - Several biotechnology and pharmaceutical names posted notable gains in Tuesday's after-hours trading session, driven by corporate updates and investor enthusiasm around clinical... ► Artikel lesen | |
| 13.01. | Rapid Micro Biosystems, Inc.: Rapid Micro Biosystems Announces Record Preliminary Unaudited Fourth Quarter and Full Year 2025 Revenue | 800 | GlobeNewswire (Europe) | Fourth quarter 2025 total revenue expected to be approximately $11.3 million, representing growth of approximately 37% compared to the prior-year period.Received record multi-system order in the fourth... ► Artikel lesen | |
| 07.11.25 | Rapid Micro Biosystems, Inc.: Rapid Micro Biosystems Reports Third Quarter 2025 Financial Results; Announces Record Multi-System Customer Order and Raises Full-Year Revenue and System Placement Guidance | 329 | GlobeNewswire (Europe) | Reports third quarter 2025 total revenue of $7.8 million, representing 3% growth compared to the third quarter of 2024. Third quarter 2025 recurring revenue, which includes consumables and annual... ► Artikel lesen |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 2,834 | 0,00 % | RALLYE bei Valneva: +37,7% Potenzial - Jetzt einsteigen? | ||
| PALATIN TECHNOLOGIES | 10,900 | 0,00 % | Wall Street Wire: StreetWatch: A $2.9 Billion Takeover Put a Spotlight on Relentless Hunger. Palatin Technologies Is Developing the Next Generation of the Drug That Seeks to Treat It | Rare-endocrine buyers have paid roughly $2.9 billion and approximately $10.0 billion for acquisitions in this area over the past four months. IMCIVREE, the only approved MC4R agonist for acquired... ► Artikel lesen | |
| OCUGEN | 0,947 | +2,05 % | Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration | The single global Phase 3 trial, ArMaDa3 (NCT07770828), is the first pivotal gene therapy trial in geographic atrophy (GA)U.S. Food and Drug Administration (FDA) granted OCU410 Regenerative Medicine... ► Artikel lesen | |
| VIVORYON THERAPEUTICS | 1,090 | 0,00 % | Vivoryon Therapeutics N.V. to Hold its 2026 Annual General Meeting on September 29, 2026 | Vivoryon Therapeutics N.V. to Hold its 2026 Annual General Meeting on September 29, 2026
Halle (Saale) / Munich, Germany, August 18, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7)... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 17,420 | -0,68 % | Biotech-Player: Zelltherapie als Comeback-Story im Milliardenmarkt. Neue Ideen nach Corona von BioNTech, Qiagen und Biotech AG | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,209 | +1,77 % | PacBio Appoints Mark Van Oene as President and Chief Executive Officer | MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) ("PacBio"), a leading developer of high-quality, highly accurate sequencing solutions,... ► Artikel lesen | |
| REDHILL BIOPHARMA | 0,568 | 0,00 % | RedHill Biopharma Ltd.: RedHill Divests Talicia to Apotex for $18 Million Cash Upfront Plus Milestones to Fuel Strategic Growth Opportunities | Executes a major step in RedHill's strategic roadmap to fundamentally reposition the Company's commercial business toward new and larger product opportunities, revenue growth and an accelerated... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 8,750 | 0,00 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| VERASTEM | 6,510 | +0,71 % | Verastem Oncology stellt auf Konferenz zweigleisige RAS-Strategie vor | ||
| OXFORD NANOPORE TECHNOLOGIES | 2,060 | +0,49 % | Oxford Nanopore Wins Preliminary Injunction Against MGI Tech Over Cyclone Sequencing Systems | ||
| ROCKET PHARMACEUTICALS | 3,070 | +4,42 % | Rocket Pharma upgraded at Needham as FDA OKs pivotal trial design | ||
| VOYAGER THERAPEUTICS | 2,674 | +0,38 % | Voyager Therapeutics, Inc.: Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer's Disease Expected H2 2026 | - Data presented as Developing Topics poster at AAIC 2026 - LEXINGTON, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging... ► Artikel lesen | |
| PALISADE BIO | 1,595 | 0,00 % | Palisade Bio stellt Pläne für CED-Medikament auf Investorenkonferenz vor | ||
| PERSONALIS | 14,290 | 0,00 % | XFRA 04X: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| XBIOTECH | 1,758 | 0,00 % | XBiotech Inc.: XBiotech startet klinische Phase-II-Studie zur Bewertung von Vilamakitug bei der Behandlung der aktiven axialen Spondyloarthritis | Der IND-Antrag für die V-SPINE-Studie hat die 30-tägige FDA-Prüfung ohne klinischen Stopp durchlaufen und ebnet damit den Weg für die Aufnahme von Patienten in den USAAUSTIN, Texas, June 15, 2026 (GLOBE... ► Artikel lesen |
Das Unternehmen RAPID MICRO BIOSYSTEMS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 1,125 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu RAPID MICRO BIOSYSTEMS INC finden Sie auf Wallstreet Online.